Document Type
Article
Department
Brain and Mind Institute
Abstract
Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer's Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. This perspective highlights the current status of this effort. Overall, amyloid (A), tau (T), and neurodegeneration (AT[N]) blood-based biomarkers have been shown to increase with disease pathology for individuals with DS. Phosphorylated tau biomarkers (p-tau217, p-tau181) have been consistently shown to track disease progression for DS-AD and are likely good candidates for use in clinical settings. Biomarkers of inflammation (glial fibrillary acidic protein) also show promise; however, additional work is needed. Findings from stability work of blood-based biomarkers conducted among non-DS also support the potential longitudinal utility of biomarkers such as neurofilament light chain and p-tau181 in DS. Gaps in our knowledge are highlighted, and a potential role for sex differences in biomarker outcomes is noted, along with recommendations for determining the appropriate context of use when translating biomarkers into clinical applications.
Publication (Name of Journal)
Journal of Alzheimer’s Disease
DOI
https://doi.org/10.1002/alz.14364
Recommended Citation
Petersen, M.,
Flores-Aguilar, L.,
Head, E.,
Montoliu-Gaya, L.,
Strydom, A.,
Pape, S.,
Fortea, J.,
Ashton, N.,
Momoh, C.,
O'Bryant, S.
(2024). Blood biomarkers in down syndrome: Facilitating alzheimer's disease detection and monitoring. Journal of Alzheimer’s Disease, 102(1), 1-11.
Available at:
https://ecommons.aku.edu/bmi/443
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Included in
Geriatrics Commons, Medical Biochemistry Commons, Neurology Commons